Literature DB >> 2611066

Pharmacokinetics of atracurium and laudanosine in the elderly.

A P Kent1, C J Parker, J M Hunter.   

Abstract

The pharmacokinetics of a bolus dose of atracurium 0.6 mg kg-1 and its metabolite laudanosine were studied in 11 elderly (mean age 80.9 yr) and 10 young patients (mean age 23.8 yr) undergoing elective surgery. The elimination half-life (T1/2 beta) of atracurium was significantly longer in the elderly group (23.1 v. 20.1 min), but there was no significant difference between the two groups in clearance (Cl), the volume of distribution (V beta) or the mean residence time (MRT) of atracurium. Laudanosine T1/2 beta was also significantly longer (229.1 v. 173.1 min) and the clearance significantly slower (4.85 v. 7.29 ml min-1 kg-1) in the elderly. There was, however, no significant difference in V beta for laudanosine between the two groups. These data suggest that atracurium depends to a small extent on the liver or the kidney for its metabolism and excretion, and that, as these routes of excretion are less efficient in the elderly, T1/2 beta is prolonged in this age group. The deteriorating function of these organs with increasing age may also explain the altered pharmacokinetics of laudanosine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2611066     DOI: 10.1093/bja/63.6.661

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  9 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  A pharmacokinetic-pharmacodynamic model for a muscle relaxant: atracurium.

Authors:  V Nigrovic; J Gaspari; M Banoub
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 3.  Anaesthesia in the elderly. Special considerations.

Authors:  A G Jones; J M Hunter
Journal:  Drugs Aging       Date:  1996-11       Impact factor: 3.923

Review 4.  Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 5.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 6.  Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice.

Authors:  H M Bryson; D Faulds
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

Review 7.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Pharmacokinetic modelling of a parent drug and its metabolite. Atracurium and laudanosine.

Authors:  V Nigrovic; M Banoub
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 9.  Neuromuscular blockade in the elderly patient.

Authors:  Luis A Lee; Vassilis Athanassoglou; Jaideep J Pandit
Journal:  J Pain Res       Date:  2016-06-17       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.